Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arrowhead Pharmaceuticals (ARWR) EBT Margin: 2010-2025

Historic EBT Margin for Arrowhead Pharmaceuticals (ARWR) over the last 15 years, with Sep 2025 value amounting to 14.08%.

  • Arrowhead Pharmaceuticals' EBT Margin fell 116567.00% to 14.08% in Q3 2025 from the same period last year, while for Sep 2025 it was 6.21%, marking a year-over-year decrease of 260734.00%. This contributed to the annual value of 6.21% for FY2025, which is 1725375.00% up from last year.
  • Latest data reveals that Arrowhead Pharmaceuticals reported EBT Margin of 14.08% as of Q3 2025, which was up 102.18% from -644.97% recorded in Q2 2025.
  • In the past 5 years, Arrowhead Pharmaceuticals' EBT Margin ranged from a high of 3,415.33% in Q2 2024 and a low of -7,004.60% during Q4 2024.
  • Moreover, its 3-year median value for EBT Margin was 14.08% (2025), whereas its average is -583.87%.
  • As far as peak fluctuations go, Arrowhead Pharmaceuticals' EBT Margin spiked by 406,862bps in 2024, and later tumbled by 406,030bps in 2025.
  • Arrowhead Pharmaceuticals' EBT Margin (Quarterly) stood at -229.13% in 2021, then skyrocketed by 16,231bps to -66.82% in 2022, then slumped by 383,881bps to -3,905.63% in 2023, then tumbled by 309,897bps to -7,004.60% in 2024, then slumped by 116,567bps to 14.08% in 2025.
  • Its EBT Margin stands at 14.08% for Q3 2025, versus -644.97% for Q2 2025 and 68.11% for Q1 2025.